Danazol (danazol)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Danazol is a synthetic derivative of ethisterone (ethinyl testosterone) with weak androgenic and anabolic properties and no estrogenic or progestogenic activity.
USES: This medication is used in women to treat pelvic pain and infertility due to a certain disorder (endometriosis) and also to treat breast pain/tenderness/nodules due to a certain breast condition (fibrocystic breast disease). It is also used in both men and women to prevent swelling of the abdomen/arms/legs/face/airway due to a certain congenital disease (hereditary angioedema). Danazol is an androgen similar to testosterone.
For the treatment of endometriosis and fibrocystic breast disease, it works by decreasing the amount of hormones made by the ovaries. These hormones usually make the conditions worse. For the treatment of angioedema, danazol helps to increase the amount of a certain protein in your body's defense system (immune system).
Generic name: danazol
Pronunciation: (DAY-nuh-zole)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Danazol
Indications
The following indications are listed for Danazol:
- Endometriosis
- Fibrocystic Breast Disease
- Prevention Of Angioedema Attacks In Patient With Hereditary Angioedema
Also known as: Adenomyosis Externa, Chronic Cystic Mastitis, Endometriosis Externa, Prevention Of Angioedema Attack In Hereditary Angioneurotic Edema, Prevention Of Angioedema Attacks In Patient With Hae, Prophylaxis Against Angioedema Attacks In Patient With Hae.
Dosing
Danazol is administered orally. For the treatment of endometriosis and fibrocystic breast disease, administration of the drug should be initiated during menstruation; otherwise, appropriate laboratory tests should be performed to ensure that the patient is not pregnant. Attempts should be made to determine the lowest possible effective dosage of the drug.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Although there are no adequate and controlled studies to date in humans, danazol may cause fetal harm when administered to pregnant women. Androgenic effects including clitoral hypertrophy, labial fusion of the external genital fold to form a scrotal-like structure, ambiguous genitalia, abnormal vaginal development, and persistence of a urogenital sinus have occurred in the female offspring of women who were given danazol during pregnancy. Spontaneous abortions have also occurred in pregnant women who received the drug. Since the risks clearly outweigh the possible benefits in women who are or may become pregnant, danazol is contraindicated in such women. Women of childbearing age should be instructed to use an effective, nonhormonal method of contraception during danazol therapy and be informed of the potential hazard to the fetus should they become pregnant during therapy. In addition, a reliable pregnancy test (e.g., beta-subunit radioimmunoassay (RIA)) must be performed immediately prior to beginning danazol therapy. If the drug is inadvertently administered during pregnancy or if the patient becomes pregnant while receiving the drug, administration of danazol should be discontinued, and the woman should be apprised of the potential risk to the fetus.
Because of the potential for serious adverse reactions to danazol in nursing infants, a decision should be made whether to discontinue nursing or not use the drug, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.